Core Operating Income Increase
Core operating income for FY2025 Q1 was JPY27.7 billion, up JPY22 billion YoY, indicating strong recurring earnings power.
Sumitomo Pharma Performance
Sumitomo Pharma's core operating income was JPY21 billion, an increase of JPY20.1 billion YoY, driven by increased shipments and operational streamlining.
Essential and Green Materials Improvement
Core operating income improved by JPY14.1 billion YoY, with profit margins improved in synthetic resins due to naphtha price drop and improved refining margins at Petro Rabigh.
Positive Cash Flow from Operating Activities
Cash flows from operating activities resulted in a positive inflow of JPY24 billion, up by JPY36.3 billion YoY, improving working capital.